The European Union declined the endorsement of a novel Alzheimer's medication.

In a significant decision, the European Medicines Agency (EMA) has refused to approve the use of the drug Aduhelm for treating Alzheimer's disease. This decision comes after more than three thousand patients with early-stage Alzheimer's disease participated in trials for the drug.

The trials, which involved patients with early-stage Alzheimer's disease, saw some participants taking Aduhelm for 20 months, while others were given a placebo. The drug was approved in the USA this summer, making it the first new Alzheimer's drug in 20 years.

However, the benefits of Aduhelm do not outweigh its risks according to the EMA. The agency's decision is based on two lengthy studies, which showed inconsistent results and did not indicate that the drug is sufficiently safe or effective in treating adults with early-stage Alzheimer's disease.

The EMA's statement also noted that some brain scans of patients who took Aduhelm showed signs of swelling or bleeding. These findings raised concerns about the drug's safety.

The World Health Organization (WHO) has also highlighted the need for improved care for people with dementia, including those with Alzheimer's disease. The global community is not currently providing adequate care for this growing population.

In response to the EMA's decision, the manufacturer of Aduhelm, Biogen, has likely announced plans to protest the rejection within the next two weeks. The company may also choose to appeal the decision, aiming to bring the new treatment to European patients with Alzheimer's disease.

This decision by the EMA is a setback for the Alzheimer's community, but it underscores the importance of thorough and rigorous testing to ensure the safety and efficacy of new treatments. As research continues, hope remains for finding effective and safe treatments for Alzheimer's disease.